Novo Nordisk Tells Patent Board Mylan Petition Is Procedurally Improper
ALEXANDRIA, Va. — A “copycat” challenge to a patent associated with the weight loss drug Ozempic filed 18 months after the petitioners were accused of infringement — and that seeks joinder...To view the full article, register now.
Already a subscriber? Click here to view full article